A new trading day began on Tuesday, with Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock price up 1.44% from the previous day of trading, before settling in for the closing price of $35.40. RARE’s price has ranged from $29.59 to $60.37 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 48.58% over the last five years. Meanwhile, its annual earnings per share averaged 17.88%. With a float of $87.56 million, this company’s outstanding shares have now reached $92.41 million.
The firm has a total of 1294 workers. Let’s measure their productivity. In terms of profitability, gross margin is 83.14%, operating margin of -95.67%, and the pretax margin is -101.31%.
Ultragenyx Pharmaceutical Inc (RARE) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.75%, while institutional ownership is 94.06%. The most recent insider transaction that took place on Mar 06 ’25, was worth 72,114. In this transaction Chief Financial Officer of this company sold 1,785 shares at a rate of $40.40, taking the stock ownership to the 106,169 shares. Before that another transaction happened on Mar 03 ’25, when Company’s CBO & EVP sold 6,028 for $42.10, making the entire transaction worth $253,779. This insider now owns 265,238 shares in total.
Ultragenyx Pharmaceutical Inc (RARE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 65.33% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Here are Ultragenyx Pharmaceutical Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.34, a number that is poised to hit -1.60 in the next quarter and is forecasted to reach -3.41 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Analysing the last 5-days average volume posted by the [Ultragenyx Pharmaceutical Inc, RARE], we can find that recorded value of 0.97 million was better than the volume posted last year of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 85.92%. Additionally, its Average True Range was 1.89.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 30.97%, which indicates a significant decrease from 82.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.76% in the past 14 days, which was higher than the 42.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.74, while its 200-day Moving Average is $46.61. Now, the first resistance to watch is $36.41. This is followed by the second major resistance level at $36.91. The third major resistance level sits at $37.49. If the price goes on to break the first support level at $35.33, it is likely to go to the next support level at $34.75. Should the price break the second support level, the third support level stands at $34.25.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
With a market capitalization of 3.37 billion, the company has a total of 93,893K Shares Outstanding. Currently, annual sales are 560,230 K while annual income is -569,180 K. The company’s previous quarter sales were 164,880 K while its latest quarter income was -133,390 K.
